Get the Stockscreener App
0.9319
0.86%
-0.0081
Pre-market:
.94
0.0081
+0.87%
Mira Pharmaceuticals Inc stock is traded at $0.9319, with a volume of 84,168.
It is down -0.86% in the last 24 hours and down -3.23% over the past month.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.
See More
Previous Close:
$0.94
Open:
$0.9598
24h Volume:
84,168
Relative Volume:
0.57
Market Cap:
$39.16M
Revenue:
-
Net Income/Loss:
$-31.37M
P/E Ratio:
-0.6481
EPS:
-1.438
Net Cash Flow:
$-4.23M
1W Performance:
-6.81%
1M Performance:
-3.23%
6M Performance:
-35.28%
1Y Performance:
-22.98%
1-Day Range:
$0.9319
$0.985
1-Week Range:
$0.9319
$1.02
52-Week Range:
$0.90
$2.45
Mira Pharmaceuticals Inc Stock (MIRA) Company Profile
Name
Mira Pharmaceuticals Inc
Sector
Industry
Phone
813-369-5150
Address
1200 BRICKELL AVENUE, MIAMI
Compare MIRA vs LLY, JNJ, ABBV, NVS, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIRA
Mira Pharmaceuticals Inc
|
0.9319 | 39.16M | 0 | -31.37M | -4.23M | -1.438 |
LLY
Lilly Eli Co
|
1,129.35 | 1.01T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
235.66 | 567.28B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
221.59 | 391.50B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
151.56 | 289.19B | 54.66B | 13.58B | 16.05B | 7.0171 |
MRK
Merck Co Inc
|
114.90 | 283.78B | 65.51B | 8.93B | 14.12B | 3.5532 |
Mira Pharmaceuticals Inc Stock (MIRA) Latest News
MIRA PHARMACEUTICALS (MIRA) director granted 50,000 stock options award - Stock Titan
MIRA Pharmaceuticals (MIRA) grants director 50,000 stock options at $0.94 - Stock Titan
MIRA Pharmaceuticals grants director 50,000 stock options | MIRA Insider Trading - Stock Titan
MIRA Pharmaceuticals Inc. (MIRA) Edges Higher: Navigating Key Levels in a Volatile SectorGolden Cross - newsline.com
MIRA Pharmaceuticals Appoints New Fractional Chief Financial Officer - The Globe and Mail
MIRA PHARMACEUTICALS (MIRA) CFO Andriy Mushak listed as insider in Form 3 - Stock Titan
Mira Pharmaceuticals appoints Andriy Mushak as fractional CFO By Investing.com - Investing.com Nigeria
Mira Pharmaceuticals appoints Andriy Mushak as fractional CFO - Investing.com
Mira PharmaceuticalsAlan Weichselbaum To Step Down As CFO Effective June 6, 2026SEC Filing - TradingView
MIRA appoints Andriy Mushak as fractional CFO as Alan Weichselbaum departs - TradingView
Mira Pharmaceuticals (NASDAQ: MIRA) hires fractional CFO via LMAM - Stock Titan
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
MIRA Pharmaceuticals Holds Steady at $1.0 as Key Support and Resistance TestedLinear Regression - newsline.com
MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1 - ACCESS Newswire
MIRA Pharmaceuticals Secures Unified Global Rights to Pipeline - TipRanks
MIRA Pharmaceuticals Secures Worldwide Exclusive Rights To MIRA-55 And SKNY-1SEC Filing - TradingView
MIRA Pharmaceuticals (NASDAQ: MIRA) consolidates worldwide exclusive rights to MIRA-55 and SKNY-1 - Stock Titan
Experimental obesity and chronic pain drugs now under MIRA's global control - Stock Titan
MIRA Pharmaceuticals Faces Subdued Sentiment as Stock Dips Toward Key SupportAccumulation Line - newsline.com
MIRA News | MIRA PHARMACEUTICALS INC (NASDAQ:MIRA) - ChartMill
MIRA Pharmaceuticals Inc. (MIRA) Slips 8.66% to $1.05 as Technicals Test Key SupportRevenue Growth Stocks - The Legal Advocate
MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN - Black Hills Pioneer
MIRA Pharmaceuticals Q3 2025 Earnings: EPS Beats Estimates Amid Narrowing Losses; Stock DeclinesEarnings Call Q&A - newsline.com
MIRA Pharmaceuticals expands Ketamir-2 license to worldwide - Investing.com UK
MIRA Pharmaceuticals expands Ketamir-2 license to worldwide By Investing.com - Investing.com Nigeria
MIRA Expands Global Ketamir-2 License for Clinical Development - TipRanks
Mira Pharmaceuticals enters into amendment no 1 to exclusive license agreement with Miralogx - marketscreener.com
MIRA Pharmaceuticals (MIRA) expands Ketamir-2 license to worldwide IP rights - Stock Titan
Experimental oral chemo nerve damage drug gets IP boost in 10 countries - Stock Titan
MIRA Pharmaceuticals Edges Higher, Consolidating Near Key Resistance at $1.04AAII Bearish - newsline.com
MIRA Pharmaceuticals Inc. (MIRA) Nears Support After Marginal DeclineRetracement Entry - The Legal Advocate
MIRA Q3 2025 Earnings: Narrower-Than-Expected Loss Lifts SharesEarnings Season Outlook - The Legal Advocate
MIRA Q3 2025 Earnings: Narrowed Loss Surpasses Expectations Amid No RevenueCFO Commentary Report - The Legal Advocate
MIRA Stock Chart | MIRA PHARMACEUTICALS INC (NASDAQ:MIRA) - ChartMill
MIRA Pharmaceuticals (MIRA) Q3 2025 Earnings: Why the Beat MattersRising Community Picks - Newser
What MIRA Pharmaceuticals (MIRA)'s +1.35% Jump Means for Investors 2026-05-18Sentiment Extreme - The Legal Advocate
What's going on with MIRA Pharma stock Tuesday? - MSN
Should You Sell MIRA Pharmaceuticals (MIRA) After -1.24% Drop? 2026-05-15Golden Cross - Newser
MIRA Pharmaceuticals (MIRA) Delivers Q3 2025 Beat — EPS $-0.06 vs $-0.08 ExpectedAnalyst Stock Picks - Newser
MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2 - Black Hills Pioneer
MIRA Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
MIRA Pharmaceuticals (MIRA) posts Q1 2026 loss and warns on going concern - Stock Titan
MIRA Pharmaceuticals reports phase 1 results for Ketamir-2 - Investing.com UK
Mira Pharmaceuticals stock gains on Phase 1 trial results By Investing.com - Investing.com South Africa
Mira Pharmaceuticals stock gains on Phase 1 trial results - Investing.com
MIRA Pharmaceuticals reports phase 1 results for Ketamir-2 By Investing.com - Investing.com Canada
Chemo nerve damage has no FDA drugs—MIRA advances new Ketamir-2 pill - Stock Titan
MIRA Pharmaceuticals Reports Positive Phase 1 Ketamir-2 Results - TipRanks
MIRA (MIRA) posts positive Phase 1 data and DEA decision on Ketamir-2 - Stock Titan
Mira Pharmaceuticals Inc Stock (MIRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.80%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):